The SEQDESIGN Procedure

Armitage, P., McPherson, C. K., and Rowe, B. C. (1969), “Repeated Significance Test on Accumulating Data,” Journal of the Royal Statistical Society, Series A, 132, 235–244.

Chow, S. C. and Liu, J. P. (1998), Design and Analysis of Clinical Trials, Concept and Methodologies, New York: John Wiley & Sons.

Chow, S.-C., Shao, J., and Wang, H. (2003), Sample Size Calculations in Clinical Research, Boca Raton, FL: CRC Press.

Cox, D. R. and Hinkley, D. V. (1974), Theoretical Statistics, London: Chapman & Hall.

DeMets, D. L., Furberg, C. D., and Friedman, L. M. (2006), Data Monitoring in Clinical Trials, New York: Springer.

Diggle, P. J., Heagerty, P., Liang, K.-Y., and Zeger, S. L. (2002), Analysis of Longitudinal Data, Second Edition, New York: Oxford University Press.

Dmitrienko, A., Molenberghs, G., Chuang-Stein, C., and Offen, W. (2005), Analysis of Clinical Trials Using SAS: A Practical Guide, Cary, NC: SAS Institute Inc.

Efron, B. and Hinkley, D. V. (1978), “Assessing the Accuracy of the Maximum Likelihood Estimator: Observed versus Expected Fisher Information,” Biometrika, 65, 457–483.

Ellenberg, S. S., Fleming, T. R., and DeMets, D. L. (2003), Data Monitoring Committees in Clinical Trials, New York: John Wiley & Sons.

Emerson, S. S. (1996), “Statistical Packages for Group Sequential Methods,” The American Statistician, 50, 183–192.

Emerson, S. S. and Fleming, T. R. (1989), “Symmetric Group Sequential Designs,” Biometrics, 45, 905–923.

Emerson, S. S., Kittelson, J. M., and Gillen, D. L. (2005), “On the Use of Stochastic Curtailment in Group Sequential Clinical Trials,” .
URL http://www.bepress.com/uwbiostat/paper243

Food and Drug Administration (1998), “E9: Statistical Principles for Clinical Trials,” Federal Register, 63 (179), 49583–49598.

Haybittle, J. L. (1971), “Repeated Assessment of Results in Clinical Trials of Cancer Treatment,” British Journal of Radiology, 44, 793–797.

Hsieh, F. Y. and Lavori, P. W. (2000), “Sample-Size Calculations for the Cox Proportional Hazards Regression Model with Nonbinary Covariates,” Controlled Clinical Trials, 21, 552–560.

Hwang, I. K., Shih, W. J., and DeCani, J. S. (1990), “Group Sequential Designs Using a Family of Type I Error Probability Spending Functions,” Statistics in Medicine, 9, 1439–1445.

Jennison, C. and Turnbull, B. W. (1990), “Statistical Approaches to Interim Monitoring of Medical Trials: A Review and Commentary,” Statistical Science, 5, 299–317.

Jennison, C. and Turnbull, B. W. (2000), Group Sequential Methods with Applications to Clinical Trials, New York: Chapman & Hall.

Kalbfleisch, J. D. and Prentice, R. L. (1980), The Statistical Analysis of Failure Time Data, New York: John Wiley & Sons.

Kim, K. and DeMets, D. L. (1987), “Design and Analysis of Group Sequential Tests Based on the Type I Error Spending Rate Function,” Biometrika, 74, 149–154.

Kim, K. and Tsiatis, A. A. (1990), “Study Duration for Clinical Trials with Survival Response and Early Stopping Rule,” Biometrics, 46, 81–92.

Kittelson, J. M. and Emerson, S. S. (1999), “A Unifying Family of Group Sequential Test Designs,” Biometrics, 55, 874–882.

Lachin, J. M. and Foulkes, M. A. (1986), “Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification,” Biometrics, 42, 507–519.

Lan, K. K. G. and DeMets, D. (2009), “Further Comments on the Alpha-Spending Function,” Statistics in Biosciences, 1, 95–111.

Lan, K. K. G. and DeMets, D. L. (1983), “Discrete Sequential Boundaries for Clinical Trials,” Biometrika, 70, 659–663.

Lan, K. K. G., Lachin, J. M., and Bautista, O. (2003), “Over-Ruling a Group Sequential Boundary: A Stopping Rule versus a Guideline,” Statistics in Medicine, 22, 3347–3355.

Lan, K. K. G., Simon, R., and Halperin, M. (1982), “Stochastically Curtailed Tests in Long-Term Clinical Trials,” Sequential Analysis, 1, 207–219.

Lindgren, B. W. (1976), Statistical Theory, Third Edition, New York: Macmillan.

McCullagh, P. and Nelder, J. A. (1989), Generalized Linear Models, Second Edition, London: Chapman & Hall.

Mehta, C. R. and Tsiatis, A. A. (2001), “Flexible Sample Size Considerations under Information Based Interim Monitoring,” Drug Information Journal, 35, 1095–1112.

O’Brien, P. C. and Fleming, T. R. (1979), “A Multiple Testing Procedure for Clinical Trials,” Biometrics, 35, 549–556.

O’Neill, R. T. (1994), Statistics in the Pharmaceutical Industry, chapter Interim Analysis, A Regulatory Perspective on Data Monitoring and Interim Analysis, 285–290, Marcel Dekker.

Pampallona, S. and Tsiatis, A. A. (1994), “Group Sequential Designs for One-Sided and Two-Sided Hypothesis Testing with Provision for Early Stopping in Favor of the Null Hypothesis,” Journal of Statistical Planning and Inference, 42, 19–35.

Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. (1976), “Design and Analysis of Randomized Clinical Trials Requiring Prolonged Observation of Each Patient: I. Introduction and Design,” British Journal of Cancer, 34, 585–612.

Pocock, S. J. (1977), “Group Sequential Methods in the Design and Analysis of Clinical Trials,” Biometrika, 64, 191–199.

Pocock, S. J. (1982), “Interim Analyses for Randomized Clinical Trials: The Group Sequential Approach,” Biometrics, 38, 153–162.

Pocock, S. J. and White, I. (1999), “Trials Stopped Early: Too Good to Be True?” Lancet, 353, 943–944.

Proschan, M. A., Lan, K. K. G., and Wittes, J. T. (2006), Statistical Monitoring of Clinical Trials, New York: Springer.

Rudser, K. D. and Emerson, S. S. (2007), “Implementing Type I and Type II Error Spending for Two-Sided Group Sequential Designs,” Contemporary Clinical Trials, 29, 351–358.

Schoenfeld, D. A. (1983), “Sample-Size Formula for the Proportional-Hazards Regression Model,” Biometrics, 39, 499–503.

Senn, S. (1997), Statistical Issues in Drug Development, New York: John Wiley & Sons.

Snapinn, S. M. (2000), “Noninferiority Trials,” Current Controlled Trials in Cardiovascular Medicine, 1, 19–21.

Wang, S. K. and Tsiatis, A. A. (1987), “Approximately Optimal One Parameter Boundaries for Group Sequential Trials,” Biometrics, 43, 193–199.

Ware, J. H., Muller, J. E., and Braunwald, E. (1985), “The Futility Index: An Approach to the Cost-Effective Termination of Randomized Clinical Trials,” American Journal of Medicine, 78, 635–643.

Whitehead, J. (1997), The Design and Analysis of Sequential Clinical Trials, Revised Second Edition, Chichester, UK: John Wiley & Sons.

Whitehead, J. (2001), Handbook of Statistics in Clinical Oncology, chapter Use of the Triangular Test in Sequential Clinical Trials, 211–228, New York: Marcel Dekker.

Whitehead, J. and Jones, D. R. (1979), “The Analysis of Sequential Clinical Trials,” Biometrika, 66, 443–452.

Whitehead, J. and Stratton, I. (1983), “Group Sequential Clinical Trials with Triangular Continuation Regions,” Biometrics, 39, 227–236.

Zhu, L., Ni, L., and Yao, B. (2011), “Group Sequential Methods and Software Applications,” The American Statistician, 65, 127–135.